Jennie Chang

Statistics

Publications

Citations

473

H-Index

Active since

2004

Affiliations

Center for Drug Evaluation and Research(Current)

United States Food and Drug Administration

Jennie Chang is an author at Center for Drug Evaluation and Research specializing in pharmacology, immune checkpoint inhibitors, and melanoma pharmacotherapy.

Publications per year

2004–2018

Publications

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis

Julia A. Beaver, Maitreyee Hazarika, Flora Mulkey et al. · The Lancet Oncology · 2018 · 177 citations · Full text

Medicine, Dermatology, Oncology +17

Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy

Jennie Chang, Judy A. Staffa, Mary Parks et al. · Pharmacoepidemiology and Drug Safety · 2004 · 152 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma

Meredith K. Chuk, Jennie Chang, Marc R. Theoret et al. · Clinical Cancer Research · 2017 · 89 citations

Medicine, Oncology, Pharmacology +17

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors

Christopher G. Rowan, Allen Brinker, Parivash Nourjah et al. · Pharmacoepidemiology and Drug Safety · 2009 · 55 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

1–4 of 4